Status:
COMPLETED
Olmesartan Medoxomil Versus Losartan in Patients With Hypertension
Lead Sponsor:
Daiichi Sankyo
Collaborating Sponsors:
Daiichi Sankyo Taiwan Ltd.
Conditions:
Essential Hypertension
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the efficacy and safety of oral administration of olmesartan medoxomil compared to losartan in subjects with mild to moderate hypertension.
Eligibility Criteria
Inclusion
- Diastolic BP 95 mm Hg - 114 mm Hg inclusive
- No participation in any clinical trial for the last 3 months
Exclusion
- Secondary hypertension
- Malignant hypertension
- Severe arterial hypertension
- Significant cardiovascular disease
- History or clinical evidence of cerebrovascular, gastrointestinal, hematological, hepatic disease, myocardial infarction, or severe liver disorder
- Clinical evidence of renal disease, poorly controlled diabetes, known malabsorption syndromes, psychiatric/emotional problems
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2003
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00857285
Start Date
May 1 2002
End Date
September 1 2003
Last Update
July 23 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan
2
Chung Shun Medical University Hospital
Taichung, Taiwan
3
National Taiwan University Hospital
Taipei, Taiwan